HNRNPH1 regulates cell cycle-associate genes in glioblastoma

Clinical trials of targeted therapy, anti-angiogenic agents, gene therapy, and immunotherapy have led to some extension of the length of GBM patient survival. However, a cure for GBM remains elusive, and almost all tumors recur in a more aggressive form for which there is no standard of care.

One critical reason for GBM resistance to current therapies can be attributed to the tumor’s extensive heterogeneity and the presence of different mechanisms that promote GBM progression. Post-transcriptional regulation of messenger RNAs participates in many cancer processes, and it is usually controlled by several different RNA-binding proteins. Dysregulation of RNA-binding protein expression alters RNA metabolism and results in the production of abnormal proteins that promote cancer development.